Amarin Corp Plc (AMRN)

[ziploc_1]

Capt...The Amarin-HLS deal has up front milestone payments to Amarin...I believe Amarin will have to pay Mochida double digit royalties but NO milestone payments...
QUOTE..."Under the Amarin-HLS agreement, HLS will be responsible for regulatory and commercialization activities and associated costs. Amarin is responsible for providing assistance towards local filings, supplying finished product, maintaining intellectual property and continuing the development and funding of REDUCE-IT. Terms of the agreement include up-front and milestone payments to Amarin of up to US$65.0 million. These payments include a non-refundable upfront payment of US$5.0 million, as well as development, regulatory and sale-based milestones totaling up to an additional US$60.0 million. The agreement also provides for HLS to pay Amarin tiered double digit royalties on net sales of Vascepa in Canada."

Since Vascepa is apparently profitable to HLS, even after shelling out milestone payments as well as royalties to Amarin...perhaps MND-2119 could be profitable to Amarin, either as a solo drug,or even better, as a combo drug with a statin...ESPECIALLY IF AMARIN COULD OBTAIN PATENT EXCLUSIVITY FOR MND-2119 IN THE U.S.